Skip to content
    WGS
    Earnings call· Jun 2026(Q2 FY26)

    GeneDx Holdings Q2 FY26 earnings call WGS

    Aug 3, 2026 Source

    Executive summary

    GeneDx Q2 FY26 — Record Volume and Return to Profitability

    GeneDx delivered a solid Q2 FY26 with record test volumes and an earlier-than-expected return to profitability, driven by strong demand and completed cost actions. The company is now intensely focused on optimizing unit economics and improving collection rates, particularly for genome testing, which saw significant payer coverage expansion. Management expects meaningful improvements in collection rates and cash flow generation in Q4 FY26 and 2027.

    Highlights

    5
    • Achieved a record of over 30,000 exome and genome tests, representing 32% year-over-year growth.

    • Reported $114.4 million in total revenue, exceeding guidance for the quarter.

    • Returned to profitability one quarter earlier than expected, with adjusted net income of $0.4 million.

    • Commercial genome coverage expanded significantly from 47% to 87% in one quarter, primarily due to Carelon's new policy.

    • Completed the full $25 million in annual cost actions committed to on the last call.

    Concerns

    3
    • Outpatient genome collection rate remained approximately 32%, flat quarter-over-quarter and down from 43% in Q2 FY25.

    • Blended average reimbursement rate was $3,258 per test, roughly flat quarter-over-quarter.

    • Whole genome testing costs nearly twice as much to produce as exome, primarily due to higher reagent costs.

    Guidance & targets

    15
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $475M-$490M
    high materiality
    High
    Full-year 2026 Exome and Genome Volume Growth
    at least 30%
    medium materiality
    High
    Full-year 2026 Exome and Genome Revenue Growth
    at least 20%
    medium materiality
    High
    Full-year 2026 Gross Margin
    approximately 70%
    medium materiality
    High
    Full-year 2026 Profitability
    profitable for the full year
    high materiality
    High
    Q3 2026 Revenue
    $122M-$124M
    high materiality
    High
    Q3 2026 Exome and Genome Revenue
    $110M-$112M
    medium materiality
    High
    Q3 2026 Exome and Genome Volume
    approximately 33,200 tests
    medium materiality
    High
    Q3 2026 Blended Average Reimbursement Rate (ARR)
    approximately $3,300 per test
    medium materiality
    High
    Q3 2026 Gross Margin
    approximately 70%
    medium materiality
    High
    Q3 2026 Adjusted Net Income
    approximately $2M
    high materiality
    High
    Collection Rates Improvement
    meaningful improvements
    high materiality
    Medium
    Cost per Test
    relatively flat
    low materiality
    Medium
    Cash Flow Generation
    returning to cash flow generation
    high materiality
    High
    Genome Mix (insurance-based outpatient volume)
    around 30%, maybe slightly lower
    low materiality
    Medium

    Operational metrics

    20
    Exome and Genome Tests Resulted
    30,000+32% YoY growth
    Q2 FY26

    New record for tests resulted.

    Total Revenue
    $114.4Mexceeding our guide
    Q2 FY26

    Total revenue for the quarter.

    Exome and Genome Revenue
    $100.3M17% YoY growth
    Q2 FY26

    Revenue specifically from exome and genome tests.

    Adjusted Net Income
    $0.4M$8.6M improvement from Q1
    Q2 FY26

    Return to profitability one quarter earlier than expected.

    Total Company Gross Margin
    70%up sequentially from 69% in Q1
    Q2 FY26

    Gross margin improvement.

    Blended Average Reimbursement Rate (ARR)
    $3,258roughly flat QoQ
    Q2 FY26

    Viewed as the new baseline for the remainder of the year.

    Genome Mix (insurance-based outpatient volume)
    32%down from close to 40% in Q1 FY26
    Q2 FY26

    Demonstrating steady mix share gains back into exome and reflex.

    Commercial Exome Coverage
    98%up from approximately 90% in Q1 FY26
    Q2 FY26

    Percentage of commercial lives with some level of exome coverage.

    Commercial Genome Coverage
    87%up significantly from 47% last quarter
    Q2 FY26

    Represents a structural shift in reimbursement outlook for genomes.

    Medicaid States Covering Exome or Genome
    39
    Q2 FY26

    Number of states with Medicaid coverage for exome or genome testing.

    Outpatient Genome Volume Submitted to Payers with Positive Coverage
    67%up from 46% in Q1 FY26 and 38% in Q2 FY25
    Q2 FY26

    Uptrend continued in July due to rolling advancements of policy coverage.

    Outpatient Genome Collection Rate
    32%flat QoQ, down from 43% in Q2 FY25
    Q2 FY26

    Reflects investment into developing the market by accepting volume ahead of coverage; tremendous opportunity for improvement.

    Outpatient Exome Collection Rate
    comparable to genome
    Q2 FY26

    Indicates significant room for improvement across the entire portfolio.

    Cost per Whole Genome Test vs. Exome
    nearly twice as much
    Q2 FY26

    Expected to come down as utilization grows and manufacturers advance technology.

    Operating Expenses
    ~$80Mslightly better than expected
    Q2 FY26

    Operating expenses for the quarter.

    Annual Cost Actions Completed
    $25M
    FY26

    Completed the full amount of cost actions committed to on the last call.

    Pro Forma Liquidity
    $188M
    as of June 30, 2026

    Includes $50M expansion of debt facility and concurrent equity investment from Blackstone Life Sciences.

    Geneticist Market Share
    ~80%
    Q2 FY26

    Maintained market share among geneticists.

    Pediatric Neurology Market Share
    ~50%
    Q2 FY26

    Expanded market share in pediatric neurology.

    Reflex Volume vs. Genome
    exceeding genomes
    July (single month basis)

    For the first time since launch, reflex volumes exceeded genomes in July.

    Industry KPIs

    1
    MetricValueDetails
    Adjusted EPS EBITDA leverage guidance$0.4MUSD

    Product announcements

    1
    ProductTypeDetails
    1-minute genome orderinglaunch

    Deals & partnerships

    1
    Blackstone Life SciencesExpansion of existing debt facility and concurrent equity investment$50M

    Fortified financial position through a $50 million expansion of existing debt facility and a concurrent equity investment from Blackstone Life Sciences.

    Risks & headwinds

    4
    Low Outpatient Collection RatesCurrent

    Outpatient genome collection rate approximately 32%, flat QoQ and down from 43% in Q2 FY25.

    Mitigation: Intense focus on improving revenue cycle management (RCM) processes, implementing payer-specific workflows, and investing in AI and technology to reach an industry standard of 70% collection rate.

    Lag in Payment from Payer Coverage ExpansionNear-term (Q3/Q4 FY26)

    Commercial genome coverage expanded from 47% to 87% in Q2, but payment lags coverage.

    Mitigation: Continued focus on RCM and operational effectiveness to translate expanded coverage into actual payment, with significant uplift expected in 2027.

    High Cost of Whole Genome ProductionCurrent

    Whole genome costs nearly twice as much to produce than exome, primarily due to higher reagent costs.

    Mitigation: Expect costs to come down as utilization for genome grows and manufacturers advance their technology, with step improvements anticipated in 2027.

    Administrative Barriers to PaymentCurrent

    Claims denied by overly restricted eligibility criteria and administrative barriers, even with written coverage policies.

    Mitigation: Building payer-specific workflows to ensure compliance with medical necessity criteria, documentation requirements, and prior authorization processes to improve approval rates and reduce avoidable denials.

    What to watch in Q3 FY26

    5

    Outpatient genome collection rate

    Q4 FY26
    Current~32%
    TargetMeaningful improvement

    Why it matters

    This is a key driver for revenue uplift and profitability, with management targeting a 70% collection rate in the long term.

    We expect to see meaningful improvements in Q4 2026 with the most significant uplift coming in 2027, as both expanded coverage and stronger operational execution compound together.

    Q&A highlights

    5

    Can you elaborate on the pacing of collection rate improvements in Q3 and Q4, and what the upside could mean for 2027?

    Management explained that there's a natural lag between operational improvements and accrual rates. Q3 collection rates are expected to remain flat, with meaningful improvements beginning in Q4 2026 and significant upside in 2027. They emphasized that the current 32% genome collection rate reflects coverage maturity, not the target, and doubling it to 70% represents a substantial opportunity.

    Look, today, at 32% genome collection rates reflect where we are in the coverage maturity, not where we think we're going.

    asked by Dan Brennan · answered by Kevin Feeley

    2 min read5 chapters

    Detailed Narrative

    01

    Optimizing Unit Economics and Revenue Cycle Management

    GeneDx is intensely focused on improving its blended average reimbursement rate, which is currently seen as underearning its potential. The strategy involves four key levers: mix management (shifting towards exome/reflex in the near term), expanding payer coverage (e.g., Carelon's significant expansion for genome), implementing payer-specific workflows to meet administrative requirements, and investing in AI and other technologies for revenue cycle operations. These actions are expected to influence rates in the coming quarters, with meaningful improvements anticipated in Q4 FY26 and significant uplift in 2027.

    02

    Commercial Strategy and Market Diversification

    The company maintains strong market leadership, holding approximately 80% market share among geneticists and expanding its pediatric neurology market share to roughly 50%. GeneDx is also strategically diversifying its call points by investing in general pediatrics, a channel that saw its highest growth ever in Q2. This expansion is driven by changes in AAP guidelines and aims to unlock the total addressable market, bringing genomic testing to patients earlier in their diagnostic journey. The company adjusts coverage models to ensure appropriate return on investment for its sales force.

    03

    Payer Coverage Expansion and Lag in Payment

    Significant progress was made in payer coverage, with commercial genome coverage expanding from 47% to 87% in Q2, primarily due to a new Carelon policy covering 56 million lives. Additionally, Medicaid coverage for exome/genome testing is now available in 39 states, with Mississippi coming online in July. While these expansions represent a structural shift in reimbursement outlook, there is a natural lag between coverage and actual payment. The full impact on blended ARR and revenue is expected to flow through more significantly in 2027.

    04

    Collection Rate Opportunity and Operational Effectiveness

    The outpatient genome collection rate stands at approximately 32%, a figure management views as a tremendous opportunity for improvement. This rate reflects the company's strategy to accept volume ahead of coverage to build clinical evidence. GeneDx aims to double this collection rate to an industry standard of 70%, which would significantly boost revenue and profitability. Operational improvements, including new revenue cycle leaders and enhanced workflows, are being implemented, with their full impact expected to compound in 2027.

    05

    Financial Fortification and Capital Management

    GeneDx fortified its financial position by expanding its existing debt facility by $50 million and securing a concurrent equity investment from Blackstone Life Sciences. This brings pro forma liquidity to approximately $188 million as of June 30, 2026, ensuring the company is fully capitalized well beyond sustained positive cash flow. The company completed $25 million in annual cost actions and expects to return to cash flow generation in Q4 FY26, with strong sustained cash generation projected for 2027.

    AI-generated summary of the company’s earnings call. Not investment advice.